299 related articles for article (PubMed ID: 21502969)
1. The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study.
Haillot O; Fraga A; Maciukiewicz P; Pushkar D; Tammela T; Höfner K; Chantada V; Gagnier P; Morrill B
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):302-6. PubMed ID: 21502969
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
3. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
4. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
[TBL] [Abstract][Full Text] [Related]
5. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
6. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
7. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F;
BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
[TBL] [Abstract][Full Text] [Related]
8. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study.
Montorsi F; Roehrborn C; Garcia-Penit J; Borre M; Roeleveld TA; Alimi JC; Gagnier P; Wilson TH
BJU Int; 2011 May; 107(9):1426-31. PubMed ID: 21348912
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
Siami P; Roehrborn CG; Barkin J; Damiao R; Wyczolkowski M; Duggan A; Major-Walker K; Morrill BB;
Contemp Clin Trials; 2007 Nov; 28(6):770-9. PubMed ID: 17761460
[TBL] [Abstract][Full Text] [Related]
10. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
[TBL] [Abstract][Full Text] [Related]
11. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study.
Chung BH; Lee SH; Roehrborn CG; Siami PF; Major-Walker K; Wilson TH; Montorsi F;
Int J Urol; 2012 Nov; 19(11):1031-5. PubMed ID: 22774774
[TBL] [Abstract][Full Text] [Related]
13. Dutasteride/tamsulosin: in benign prostatic hyperplasia.
Keating GM
Drugs Aging; 2012 May; 29(5):405-19. PubMed ID: 22550968
[TBL] [Abstract][Full Text] [Related]
14. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study.
Becher E; Roehrborn CG; Siami P; Gagnier RP; Wilson TH; Montorsi F
Prostate Cancer Prostatic Dis; 2009; 12(4):369-74. PubMed ID: 19901936
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.
Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Wang F; Palacios JM; Vasylyev A; Manyak MJ
BJU Int; 2015 Sep; 116(3):450-9. PubMed ID: 25565364
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of single-dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK.
Walker A; Doyle S; Posnett J; Hunjan M
BJU Int; 2013 Sep; 112(5):638-46. PubMed ID: 23356792
[TBL] [Abstract][Full Text] [Related]
17. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
18. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
[TBL] [Abstract][Full Text] [Related]
19. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the combination of avodart and tamsulosin (CombAT) study.
Woo H
BJU Int; 2011 May; 107(9):1431. PubMed ID: 21518231
[No Abstract] [Full Text] [Related]
20. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
